These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 3142074

  • 1. Immunopurification of human factor VIII/vWF complex from plasma.
    Mejan O, Fert V, Delezay M, Delaage M, Cheballah R, Bourgois A.
    Thromb Haemost; 1988 Jun 16; 59(3):364-71. PubMed ID: 3142074
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Progress in large-scale purification of factor VIII/von Willebrand factor concentrates using ion-exchange chromatography.
    Mori F, Nardini I, Rossi P, Nardini C, Farina C.
    Vox Sang; 2008 Nov 16; 95(4):298-307. PubMed ID: 19138259
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The interaction of the factor VIII/von Willebrand factor complex (VIII/vWf), with guanidinium-derivatized matrices.
    Saundry RH, Savidge GF.
    Bioseparation; 1991 Nov 16; 2(3):177-86. PubMed ID: 1368084
    [Abstract] [Full Text] [Related]

  • 6. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G, Carretero M, Magallón M, Quintana M, Arnau C, Castillo R, Aznar-Salatti J.
    Haematologica; 1998 Nov 16; 83(11):1009-14. PubMed ID: 9864923
    [Abstract] [Full Text] [Related]

  • 7. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I, Farrugia A, Tran E, Anastasius V, Charnock A.
    Biologicals; 1998 Jun 16; 26(2):155-66. PubMed ID: 9811523
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
    Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, Ciavarella N, De Rosa V, Arter A.
    Thromb Haemost; 1993 Aug 02; 70(2):270-2. PubMed ID: 8236134
    [Abstract] [Full Text] [Related]

  • 10. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR, Tuller J, Johnson JA.
    Haemophilia; 1999 Mar 02; 5(2):88-95. PubMed ID: 10215955
    [Abstract] [Full Text] [Related]

  • 11. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
    Houdijk WP, Sakariassen KS, Nievelstein PF, Sixma JJ.
    J Clin Invest; 1985 Feb 02; 75(2):531-40. PubMed ID: 3919060
    [Abstract] [Full Text] [Related]

  • 12. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic.
    Kawasaki T, Kaida T, Arnout J, Vermylen J, Hoylaerts MF.
    Thromb Haemost; 1999 Feb 02; 81(2):306-11. PubMed ID: 10064011
    [Abstract] [Full Text] [Related]

  • 13. Isolation of the factor VIII-von Willebrand factor complex directly from plasma by gel filtration.
    Kaersgaard P, Barington KA.
    J Chromatogr B Biomed Sci Appl; 1998 Sep 18; 715(2):357-67. PubMed ID: 9792522
    [Abstract] [Full Text] [Related]

  • 14. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
    Rivera J, Escolar G, Casamiquela R, Bravo MI, Jorquera JI, Castillo R, Ordinas A, Vicente V.
    Haematologica; 1999 Jan 18; 84(1):5-11. PubMed ID: 10091386
    [Abstract] [Full Text] [Related]

  • 15. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE.
    Biologicals; 2006 Dec 18; 34(4):281-8. PubMed ID: 16500114
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
    Weiss HJ, Pietu G, Rabinowitz R, Girma JP, Rogers J, Meyer D.
    J Lab Clin Med; 1983 Mar 18; 101(3):411-25. PubMed ID: 6186757
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U, Metzner HJ, Müller HG.
    Semin Thromb Hemost; 2006 Sep 18; 32(6):626-35. PubMed ID: 16977573
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.